Симуляция графика K-линий, фактические данные указаны на торговой странице
Ключевые данные
Открытие вчера
$7.87
Пред. закрытие
$9.32
Вчерашний диапазон
$7.80 - $9.80
Диапазон 52 нед.
$5.37 - $17.58
Объем торговли
3.105M
МС
$537.375M
P/E
--
EPS
$-5.33
Обзор компании
NYSE
Ginkgo Bioworks Holdings (DNA) is a leader in synthetic biology, specializing in advanced genetic engineering to develop tailor-made bioengineered organisms for diverse applications, including pharmaceuticals, agriculture, and industrial biotech. Its cutting-edge platform enhances cellular design for efficient manufacturing processes, positioning the company to meet pressing global challenges such as climate change and food security. Ginkgo's unique capabilities and focus on sustainable biotechnology solutions not only address growing market demands for bio-based alternatives but also signify a compelling growth trajectory, underscoring its potential to drive transformative impact across multiple industries.
СекторHEALTHCARE
ОтрасльBIOTECHNOLOGY
Штаб-квартира27 DRYDOCK AVENUE, BOSTON, MA, UNITED STATES, 02210
Ginkgo Bioworks specializes in synthetic biology, developing software platforms to program cells for a wide range of applications in pharmaceuticals, agriculture, food, and industrial biotechnology. It operates within the biotechnology sector, leveraging its capabilities to enhance production processes and create new bioengineered products.
Ginkgo Bioworks primarily generates revenue through its cell programming services and partnerships with companies in diverse industries. It earns income by licensing its biotechnology platforms, delivering R&D services, and sharing in the commercial success of the products developed using its technology.
Ginkgo Bioworks stands out for its unique focus on platform-based synthetic biology and its ability to scale cell engineering through automation and data analytics. Its proprietary technology enables faster and more cost-effective development compared to traditional methods. Competitors may include other biotech firms specializing in genetic engineering or industrial applications, but many lack this integrated platform approach.
Risks include the relatively high R&D costs inherent to biotechnology, uncertainties surrounding the commercialization of new applications, and potential regulatory hurdles. Additionally, broader market conditions impacting biotech investments and competition in synthetic biology could affect the company’s financial performance over time.
No, Ginkgo Bioworks does not currently pay dividends. As a growth-focused biotechnology company, it reinvests earnings into research, development, and scaling its business operations to expand its market presence and capabilities.
Key opportunities for Ginkgo Bioworks include expanding its partnerships across industries, leveraging synthetic biology for emerging applications such as sustainable chemicals, and scaling its platform for new markets. Increased demand for bioengineering could also drive long-term growth in sectors like healthcare and agriculture.
Investors should examine metrics such as revenue growth, R&D spending, partnership activity, and operating margins. As a biotech firm, Ginkgo's success depends on its ability to convert its technology into profitable commercial applications while managing costs and development timelines effectively.
The competitive landscape includes biotech companies focused on genetic engineering and industrial biology. Some competitors may specialize in specific applications such as pharmaceuticals, agricultural biotechnology, or bio-based chemicals. Ginkgo’s differentiation lies in its scalable platform approach, which offers broad applicability across multiple industries.
Предупреждение о рисках
1.Цены на акции могут сильно колебаться, инвестируйте осторожно. Прошлые результаты не гарантируют будущую доходность.
2.Торговля цифровыми активами сопряжена с рыночными, техническими и иными рисками. Пожалуйста, принимайте взвешенные решения и рационально распределяйте активы.
3.Информация на этой странице предназначена только для ознакомления и не является инвестиционной рекомендацией.
